EE132 Economic Outcomes and Real-World Adherence of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises Treated With L-Glutamine, Voxelotor, and Crizanlizumab in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.431
https://www.valueinhealthjournal.com/article/S1098-3015(24)00546-1/fulltext
Title :
EE132 Economic Outcomes and Real-World Adherence of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises Treated With L-Glutamine, Voxelotor, and Crizanlizumab in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00546-1&doi=10.1016/j.jval.2024.03.431
First page :
Section Title :
Open access? :
No
Section Order :
11778